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ABSTRACT
Objective: Pharmaceutical sector is playing a key role toward the wellness of the people and economic development of India. The innovation, 
development, production, and marketing of medicines are accountable to the pharmaceutical industry. It is the duty of the government to ensure the 
availability of the lifesaving drugs at reasonable prices by means of considering the interest of both the producers and the buyers. To safeguard the 
public health, the National Pharmaceutical Pricing Authority (NPPA) is the watchdog in India, which controls the prices of drugs. The main objective 
of this study is to ascertain the various roles played by the NPPA, to control the prices of the drugs in India.
Methods: Data and information about “Revenue of Indian Pharmaceutical Sector,” Pharmaceutical and Healthcare Industry in India, NPPA, and Drug 
Price Control Order (DPCO) were collected and used for this study. This study is based on the information from various secondary sources.
Results: In India, prices of the medicines are controlled, and price maximum for the essential medicines are set by the Indian government using DPCO. 
List of drugs in the National List of Essential Medicines (NLEM) is expanded. In India, NPPA controls the prices of NLEM and also controls the price 
increases of non-essential medicines.
Conclusion: Pharmaceutical companies can think of reducing the expenses to reduce the cost of drugs to comply with the government drug pricing 
policy. To ensure the affordability of medicines along with the pricing policy, the Indian government may look and concentrate on the other important 
areas of pharmaceutical sectors.
Keywords: Pharmaceutical sector, Price, Drugs, Regulator, National pharmaceutical pricing authority, Drug price control order.
INTRODUCTION
Price is one of the important marketing mix elements along with 
product, physical distribution, and promotion. It is obvious that price 
fetches revenue to organizations. When organization fixes price for its 
product, they have to keep their pricing objectives in their mind. By and 
large customers tend to associate quality with the price of any product. 
According to Philip Kotler, before selling the product through price, 
marketers have to sell the price. This may not be exactly applicable and 
extended to pharmaceutical products. The government is responsible 
for ensuring the availability of drugs, especially lifesaving at affordable 
price apart from meeting the interest of producers of pharmaceutical 
products.
As per the report of Indian Brand Equity Foundation (IBEF, 2016), 
from US$6 billion in the year 2005, the Indian pharmaceuticals market 
improved at a CAGR of 17.46% in 2015. Indian pharmaceuticals market 
is anticipated to develop at a CAGR of 15.92% to US$ 55 billion by 2020. 
Revenue of Indian Pharmaceutical Sector is given in Fig. 1. In Indian 
pharmaceutical sector, generic drugs have 70% of market share in 
terms of revenue and of total market revenues of US$ 20 billion, over 
the counter medicines (OTC) and patented drugs comprise of 21% and 
9%, respectively (IBEF 2016) [1]. Revenue of Indian Pharmaceutical 
sector is given in Figure 1.
While setting the price for any product factors such as cost of 
production, cost of distribution, offering of the competitor, positioning 
strategy, and target customer have to be considered (April Maguire, 
2015) [2]. To bring down the expenses of healthcare, the Government 
of India is taking a lot of initiative. The pharmaceutical market in India 
with Rs. 98,000 crore worth may face some problems because of the 
Government of India regulatory policy like banning of some drugs, 
controlling prices, and withdrawing tax benefits (Rajagopal, 2016) 
[3]. According to Scangos, prices of the medicines will be fixed as per 
the value they fetch to patients and innovative drugs which make a 
difference in the lives of patients continue to acquire good pricing, Eric 
Fry, 2015 [4]. Revenue share of Indian pharmaceutical sub-segments in 
2015 is given in Figure 2.
Pharmaceutical and healthcare industry in India
In India, healthcare is one of the major sectors from the perspective 
of revenue and employment which includes hospitals, medical devices, 
clinical trials, telemedicine, medical equipment, health insurance, 
medical tourism, and outsourcing (IBEF, 2015) [5]. Hospitals, nursing 
homes and diagnostics centers, and pharmaceuticals constitute 65% 
of the overall market come under healthcare delivery (IBEF, 2015) [5]. 
To promote healthcare industry, the Government of India decided to 
open 3,000 medical stores across the country to offer quality medicines 
at reasonable prices (IBEF, 2015) [5]. By 2020, the Indian healthcare 
market is anticipated to develop to US$ 280 billion from the current 
worth of US$ 100 billion (IBEF, 2015) [5]. Due to rising consumer 
spending, rapid urbanization, and increasing healthcare insurance 
among others, by 2025, the Indian pharmaceutical sector is expected 
to develop to US$100 (IBEF, 2016) [6]. Moreover, cost of production of 
pharmaceutical sector in India is considerably lesser than that of the US 
and almost half of that of Europe (IBEF 2016) [7]. As far as the global 
pharmaceuticals sector is concerned, India enjoys a significant position. 
The pharmaceutical market as the industry is highly fragmented in 
India which needs to be consolidated. The government has to control 
the price of essential lifesaving drugs affordable to all section of the 
society. At the same time, the government has to safeguard the interest 
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and welfare of the drug manufacturers in India. According to industry 
officials, the Government of India’s recent policy measure such as 
banning some drugs, controlling prices and withdrawing tax benefits 
with regard to pharmaceutical sector may affect the growth of Rs.98,000 
crore pharmaceutical market, negatively affect the consolidation and 
Make in India Initiative, Rajagopal, (2016). According to Ms. Menghaney, 
Intellectual Property Right policy in India fails to acknowledge that IP is 
a market-driven model with regard to drugs for neglected disease, and 
there will be severe obstructions to access to drugs with this approach, 
Krishnan, 2016 [8].
If the medicine is deemed unaffordable, among other conditions, under 
the Indian Patents Act, a compulsory licensing (CL) can be issued for a 
drug, and the government grants permission to qualified generic drug 
makers to manufacture it. With regard to CL, India has issued only for 
a cancer drug (l) [9].
National Pharmaceutical Pricing Authority (NPPA)
Through the Government of India Resolution on August 29, 1997, The 
NPPA was established, and NPPA is responsible for the implementation 
of the National Pharmaceutical Pricing Policy, 2012 and the drugs 
prices control order (DPCO), 2013, Bhupendra Singh, Chairman, NPPA. 
NPPA safeguard the interest of producers and consumers by means 
of ensuring the sufficient availability lifesaving drugs at affordable 
prices [10]. Prices of any products can be based on cost and demand 
and supply of any product in general. As different to cost-based 
mechanism under DPCO 1995, market-based pricing mechanism 
was provided by DPCO 2013. As on June 10, 2016, NPPA fixed and 
notified the ceiling price of 330 formulations from the medicines in 
National List of Essential Medicines (NLEM)-2015 NLEM. As per NPPA 
Chairman Shri. Singh, IAS message, 969 scheduled formulations are 
under direct price control, as on date. It is the duty and responsibility 
of the government to ensure the availability of especially lifesaving 
medicines at affordable prices. According to the chairman, “the 
primary aim of the NPPA is to ensure adequate availability of essential 
and lifesaving drugs at affordable prices and in doing so, it carefully 
balances the interests of both the producers and the consumers.” 
NPPA cuts the prices of the drugs used for the treatment of diseases 
such as cancer, diabetes, and BP by about 25% and also increased 
the prices of intravenous injection fluids such as glucose and sodium 
chloride (The Hindu, June 7, 2016. p. 15). Because of the price limit 
declared by NPPA, products of the major pharma firms in India will be 
affected (The Hindu, June 7, 2016. p. 15). In general, firms selling price 
depends on average costs and the customer’s perceived value of the 
product in comparison to his or her perceived value of the competing 
products [11].
To review the DPCO 2013, Government of India formed 
an inter-ministerial committee, following the Supreme Court verdict 
that termed the drug pricing policy as irrational and unreasonable [12].
Because the complaints about pharma companies making enormous 
profit, the inter-ministerial committee would look into the drug pricing 
mechanism [12]. The Supreme Court had observed that the Center 
was fixing maximum price of a medicine above the retail price of the 
leading company while hearing the petition of NGO All India Drug 
Action Network [12]. The inter-ministerial committee, particularly 
in the market-based pricing formula, examines the pricing of 
medicines [12]. This committee comprises representatives from DIPP 
(Department of Industrial Policy and Promotion), Ministry of Health, 
NNPPA, and Department of Pharmaceuticals (DoP) [12]. According to 
NGO (“All India Drug Action Network”), market-based pricing made the 
pricing of the medicines costlier than for any price control purposes. 
Prices of the drugs meant for lifesaving diseases such as diabetes and 
tuberculosis need to be included in the government regulatory price 
list. Under this new policy, simple average “Ceiling Prices,” in many 
cases, are higher than the market leader price, according to NGO and 
the profit margin for pharma companies and dealers has become in 
the range of 10-1300% [13]. The NGO required a direction to the 
government to carry on with earlier “cost-based pricing” to arrive 
at “ceiling prices” for all essential drugs [13]. Drug price regulator 
NPPA fixes the ceiling price of essential medicines of schedule-1, as 
stipulated under DPCO 2013 [14]. The authority fixed the ceiling price 
of 530 formulations from the list and no one is authorized to sell any 
scheduled medicine to a consumer at a price higher than the one 
notified by NPPA under the order [14].
To ensure the availability of the scheduled bulk drugs at a fair price 
from different manufacturers, prices are fixed by the NPPA as per par 3 
Fig. 1: Revenue of Indian Pharmaceutical Sector (US $ billion)
Source: Department of Pharmaceuticals, PWC, McKinsey, TechSci 
Research. F: Forecast, CAGR: Compound Annual growth rate. 
http://www.ibef.org/industry/pharmaceutical-india.aspx 
referred on 11/05/16
Fig. 2: Revenue share of Indian pharmaceutical sub-segments in 
2015 (%)
Source: Business Monitor International, FCCI Indian Pharma 
Summit 2014-15, TechSci Research. http://www.ibef.org/
industry/pharmaceutical-india.aspx referred on 11/05/16
Fig. 3: Drugs in India
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of DPCO, 1995 and also prices are fixed from time to time by notification 
in official Gazette [15]. Steps such as “Identification of bulk drugs, 
collection of data, preparation of actual cost statement, preparation 
of technical parameters, preparation of estimated cost, calculation 
of fair price of bulk drug, fixation of maximum sale price of the drug, 
and notification of bulk drug price in official Gazette” are involved in 
fixation/revision of bulk drug prices [15]. Applications received in 
NPPA from manufacturers in Form III and importers in Form IV of DPCO 
are considered for price fixation [15].
The retail prices of formulations are worked out as per the formula 
given in para 7 of DPCO, 1995 viz.
“R.P. = [M.C.+C.C.+P.M.+P.C.] × [1+MAPE/100] + E.D.”
Where, RP: Retail price stands for - RP, MC: Material cost, CC: Conversion 
cost, PM: Packaging material cost, PC: Packaging charges, MAPE: 
Maximum allowable post-manufacturing expenses, and ED: Excise duty 
stands for ED [15].
Market-based pricing is defined as a process of setting prices of 
goods/services based on the current market conditions, and prices 
are set according to mutual decision between sellers and buyers 
[28]. DPCO released by the India’s DoP in May 2013, increased the 
number of essential medicines on the NLEM, and offered a new 
idea for determining and implementing the price ceilings while 
preserving the constant supply of drug [17]. Drugs in India are given 
in Figure 3.
The three main aims of DPCO are expanding the NLEM, authorizing 
the NPPA to control prices of India’s NLEM, and authorizing the NPPA 
to control price increases of non-essential medicines [17]. There were 
348 medicines listed in NLEM 2011 which now contains a total of 376 
medicines in NLEM 2015 [18]. NPPA in India exempted drugmaker 
Wockhardt’s three insulin products from price controls for 5 years 
from January 8, 2015, and Wockhardt had applied to the NPPA for 
non-application of the price control provisions [19]. The government 
issued a new DPCO which effectively brings close to 200 more drug 
formulations under regulation and NPPA mandated to fix or revise 
prices of controlled bulk drugs and formulations, and to enforce 
prices and availability of medicines in the country, beside monitoring 
prices of decontrolled drugs, to keep these at reasonable levels. 
Previously government added 106 and removed 70 medicines from 
earlier one of 2011 increasing the list to 376 from 348 [20]. India’s 
drug pricing regulator NPPA was planning to coordinate with state 
governments across the country to combat overcharging by drug 
makers and also recently revised rates of several medications. NPPA 
fined nine drug firms with $372 million for overcharging customers 
and also imposed a penalty after the drug makers, which included 
Ranbaxy, Dr. Reddy’s, Glenmark, Cipla, and Cadila, were reportedly 
overcharging patients for doxofylline [21]. 277 medicines came under 
the regulation as per the new DPCO 2016, which was notified on 
March 2014 [22]. Indians were able to realize the reduction in their 
medical expenses due revised price of the drugs, and pharmaceutical 
companies are struggling to follow the new rule [22]. The new DPCO 
2016, notified on March 14, which brought a total 277 medicines 
under the regulation [22]. From May 2016, Indians saw a sharp fall 
in their medical expenses as the revised price for all drugs came into 
effect even as pharma companies are struggling to comply with the 
new rule [22]. Ceiling price for the 103 drugs had been revised by 
NPPA for HIV/AIDS, bacterial infections, tuberculosis, high blood 
pressure, epilepsy, Hepatitis C, and Diabetes [22]. Because of the 
revised prices of NPPA, about 70 drugs would become cheaper, and 
NPPA retro pricing order has thrown the pharma industry in a tricky 
situation [22].
CONCLUSION
In India, prices of the medicines are controlled and price maximum for 
the essential medicines are set by the Indian government using DPCO. 
It is the responsibility of the government to safeguard the interest of 
pharma companies and also to ensure the availability of essential 
medicines at an affordable price to all sections of the society. To sustain 
and excel, pharmaceutical companies in India have to formulate 
strategy according to the policy of Indian government. Pharmaceutical 
companies can think of reducing the expenses to reduce the cost of 
drugs to comply with the government drug pricing policy. To ensure 
the affordability of medicines along with the pricing policy Indian 
government may look and concentrate on the other important areas of 
pharmaceutical sectors.
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